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to ﬁrst line therapy with tacrolimus/steroids is high. How-
ever, a substantial number of patients required salvage treat-
ment and mortality continues to be high. Earlier intervention
for the prevention of both acute and chronic forms of GvHD is
warranted.
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PENTOSTATIN AND CYCLOSPORINE, A NEW REGIMEN FOR THE
PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL TRANSPLAN-
TATION
Schwartz, J.E., Carroll, M.P., BuchBarker, D.M., Grifﬁn, D.L.,
Schwartz, R.N., Tompkins, C.A., Donnenberg, A.D., Agha, M.E.,
Evans, C., Burgunder, M.R., Yeager, A.M. University of Pittsburgh
Cancer Institute, Pittsburgh, PA.
Acute graft-versus-host disease (AGVHD) is a major cause of
morbidity and mortality after allogeneic hematopoietic cell
transplantation. Common preventive strategies include cyclo-
sporine (CSP) or tacrolimus plus short-course iv methotrexate
(MTX). Pentostatin (PEN), a purine nucleoside analog, has
been used to treat steroid-refractory acute and chronic GVHD
but not to prevent AGVHD. We conducted a phase II study to
evaluate the efﬁcacy of short-course PEN plus CSP for GVHD
prophylaxis in 10 patients (pts) (6 M, 4 F; median age 34 yr;
range 18-49 yr) with AML(1), ALL(2), CML(2), NHL(3)
MM(2) who were undergoing allogeneic PBPCT from HLA-
identical sibs. Preparative regimens were: busulfan (BU) and
cyclophosphamide(CY) (5); total body irradiation(TBI) and CY
(2); BU, CY and etoposide (2); or TBI and melphalan (1). All pts
received CSP, initially by continuous iv infusion, beginning at
day (d) –2. PEN was administered i.v. at a dose of 1.0 mg/m2 on
d1 and at a dose of 0.5 mg/m2 on d3, 6 and 11. Pts
received a median of 9.24 (range, 5.38–13.9) x 106 CD34
cells/kg and a median of 3.52 (range 2.03–6.02) x 108 CD3
cells/kg. Median time to absolute lymphocyte count (ALC) 0.2
x 109/L was 9d (range, 0-13 d) after PBPCT and to absolute
neutrophil count (ANC) 0.5 x 109/L was 10d (range, 8-15 d).
In 9 pts, the median time to attain platelets 20 x 109/L was 16d
(range, 10-27 d); 1 pt never had platelet recovery. Grades of
AGVHD were: 0 (2), I (1), II (3), III (3) and IV (1). The
incidence of Grade II-IV AGVHD was 70% and of Grade
III-IV AGVHD was 40%. AGVHD responded to steroids in 3
pts but was steroid-refractory in 4 pts, requiring mycophenolate
mofetil (MMF; 2 pts) or MMF plus anti-thymocyte globulin (2
pts). Two pts died from GVHD-related complications at d108
and d112 after PBPCT. All 8 evaluable pts developed chronic
GVHD (CGVHD; 2 limited, 6 extensive); extensive CGVHD
developed in 3 pts after intentional withdrawal of immunosup-
pression and in 1 pt because of non-compliance with CSP.
Three pts (1 AML, 1 ALL, 1 MM) relapsed at d180, 188 and
266, respectively; 2 attained remissions after immunosuppres-
sion withdrawal. Eight pts are alive at a median of 443 d
(range, 181–721 days) after PBPCT (overall survival, 80%).
We conclude that PEN may be an alternative to MTX for
AGVHD prophylaxis. The observed incidence of Grade II-IV
AGVHD and of CGVHD suggests that higher doses and/or
longer duration of PEN may be needed to improve efﬁcacy of
this regimen.
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COMPARISON OF LYMPHOID AND MYELOID ENGRAFTMENT RATES IN
PATIENTS RECEIVING FLUDARABINE/TBI OR FLUDARABINE/CYCLO-
PHOSPHAMIDE FOR NON-MYELOABLATIVE ALLOGENEIC TRANSPLAN-
TATION
Mellon-Reppen, S., Dansey, R., Abella, E., Nehlsen-Cannarella, S.,
Abidi, M.H. Karmanos Cancer Institute, Detroit, MI; Wayne State
University, Detroit, MI.
Non-myeloablative allogeneic transplants are used in place of
ablative transplants in selected patients with poor performance
status or abnormal vital organ function. They have been per-
formed in patients with low grade NHL, Hodgkin’s disease,
multiple myeloma and renal cell carcinoma. The conditioning
regimen is an important element of the procedure as it contrib-
utes to the speed and rate of donor lymphoid and myeloid
engraftment.
We report engraftment and GVHD rates of ﬂudarabine/TBI
(FluTBI) compared to ﬂudarabine/cyclophosphamide (FluCy).
From 09/2000 to the present, ﬂudarabine 30mg/m2 x 3 days
with TBI 200cGy was given to 12 patients and ﬂudarabine
25mg/m2 x 5 days with cyclophosphamide 60mg/m2 x 2 days was
given to 28 patients. Post-transplant immunosuppression was
identical for both regimens with mycophenolate and cyclo-
sporine. Diagnoses included renal cancer 13, myeloma 7, NHL
6, AML/MDS 4, breast cancer 3, Hodgkin’s disease 3, CLL 2,
CML 1 and pancreatic cancer 1. Twenty three donors were
siblings and 17 were unrelated volunteers. Lymphoid and
myeloid engraftment were evaluated by peripheral blood STR
and expressed as percent donor cells. Results are reported as
median values. By ANOVA testing there are signiﬁcant differ-
ences between conditioning regimens for lymphoid engraftment
at day 14 (p  0.027) and day 28 (p  0.024). The range of
percent donor lymphoid cells was similar for both regimens at
all time points. Two (17%) patients who received FluTBI re-
jected the graft. One patient was reconditioned successfully with
FluCy. No patients receiving FluCy rejected. Acute graft versus
host disease occurred in 66% of patients conditioned with
FluCy compared to 58% (p  NS) receiving FluTBI and
chronic graft versus host disease occurred in 45% of FluCy
patients versus 50% (p  NS) of FluTBI patients. Twelve (29%)
patients have achieved CR with no difference (28% FluCy vs
33% FluTBI) between conditioning regimens.
FluCy is associated with signiﬁcantly more rapid donor lymphoid
engraftment and this is potentially important when attempting to
balance regimen morbidity with need for engraftment due to
disease progression.
125
ABSENCE OF INDUCIBLE COSTIMULATOR ON ALLOREACTIVE T CELLS
REDUCES GRAFT-VERSUS-HOST-DISEASE WHILE LEAVING GRAFT-VER-
SUS-TUMOR ACTIVITY INTACT
Tjoe, K.H., Eng, J.M., Alpdogan, O., Muriglan, S.J., Hubbard, V.M.,
Kochman, A.A., Schiro, R., van den Brink, M.R.M. Memorial Sloan-
Kettering Cancer Center, New York, NY.
Inducible costimulator (ICOS) has been recognized as a costimu-
latory molecule essential in T cell activation. Studies with ICOS
inhibition or ICOS
/
 recipients have demonstrated prolonged
allograft survival after heart or liver transplantation in animal
models. We hypothesized that inhibition of ICOS on alloreactive
Table. Engraftment Data Related to Conditioning Regime
Day Post-BMT 14 30 60 90 180 360
% Donor lymphoid FluCy 95 95 95 100 100 100
% Donor lymphoid FluTBI 63 78 87 75 100 100
% Donor myeloid FluCy 95 94 95 100 100 100
% Donor myeloid FluTBI 55 100 99 100 100 100
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